Medicare beneficiaries are more likely to receive bevacizumab instead of ranibizumab for the treatment of diabetic macular edema, according to a study.
In a sample of Medicare beneficiaries from the Medicare Part B claims from 2010 to 2013, a greater proportion of patients with DME were treated with Avastin (bevacizumab, Genentech) compared with Lucentis (ranibizumab, Genentech). The sample included 5,290 Medicare beneficiaries with DME, of which 86.4% were treated with bevacizumab and 13.6% were treated with ranibizumab.
Geographic variations were examined by the researchers by comparing
Uncategorized